A
Andrew S Duncombe
Researcher at University Hospital Southampton NHS Foundation Trust
Publications - 51
Citations - 3683
Andrew S Duncombe is an academic researcher from University Hospital Southampton NHS Foundation Trust. The author has contributed to research in topics: Chronic lymphocytic leukemia & Population. The author has an hindex of 22, co-authored 48 publications receiving 3235 citations. Previous affiliations of Andrew S Duncombe include Southampton General Hospital & University of Southampton.
Papers
More filters
Journal ArticleDOI
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Thomas Ernst,Andrew Chase,Andrew Chase,Joannah Score,Joannah Score,Claire Hidalgo-Curtis,Claire Hidalgo-Curtis,Catherine Bryant,Catherine Bryant,Amy V. Jones,Amy V. Jones,Katherine Waghorn,Katherine Waghorn,Katerina Zoi,Fiona M. Ross,Fiona M. Ross,Andreas Reiter,Andreas Hochhaus,Hans G. Drexler,Andrew S Duncombe,Francisco Cervantes,David Oscier,Jacqueline Boultwood,Francis H. Grand,Francis H. Grand,Nicholas C.P. Cross,Nicholas C.P. Cross +26 more
TL;DR: In this article, the finding of homozygous EZH2 mutations in 9 of 12 individuals with 7q acquired uniparental disomy was described, and the mutations resulted in premature chain termination or direct abrogation of histone methyltransferase activity.
Journal ArticleDOI
Mutations and prognosis in primary myelofibrosis
Alessandro M. Vannucchi,Tl Lasho,Paola Guglielmelli,Flavia Biamonte,Animesh Pardanani,Arturo Pereira,Christy Finke,Joannah Score,Naseema Gangat,Carmela Mannarelli,Rp Ketterling,Giada Rotunno,Ra Knudson,Mc Susini,Rr Laborde,Ambra Spolverini,Alessandro Pancrazzi,Lisa Pieri,Rossella Manfredini,Enrico Tagliafico,Roberta Zini,Amy V. Jones,Katerina Zoi,Andreas Reiter,Andrew S Duncombe,Daniela Pietra,Elisa Rumi,Francisco Cervantes,G Barosi,Mario Cazzola,Nc Cross,Ayalew Tefferi +31 more
TL;DR: Mutational profiling for ASXL1, EZH2, SRSF2 and IDH identifies PMF patients who are at risk for premature death or leukemic transformation.
Journal ArticleDOI
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.
Paola Guglielmelli,Terra L. Lasho,Giada Rotunno,Joannah Score,Carmela Mannarelli,Alessandro Pancrazzi,Flavia Biamonte,Animesh Pardanani,Katerina Zoi,Andreas Reiter,Andrew S Duncombe,Tiziana Fanelli,Daniela Pietra,Elisa Rumi,Christy Finke,Naseema Gangat,Rhett P. Ketterling,Ryan A. Knudson,C A Hanson,Alberto Bosi,Arturo Pereira,Rossella Manfredini,Francisco Cervantes,Giovanni Barosi,Marie Cazzola,Nicholas C.P. Cross,Alessandro M. Vannucchi,Ayalew Tefferi +27 more
TL;DR: It is concluded that the ‘number’ of prognostically detrimental mutations provides added value in the combined molecular and clinical progNostication of PMF.
Journal ArticleDOI
EZH2 mutational status predicts poor survival in myelofibrosis
Paola Guglielmelli,Flavia Biamonte,Joannah Score,Joannah Score,Claire Hidalgo-Curtis,Claire Hidalgo-Curtis,Francisco Cervantes,Margherita Maffioli,Tiziana Fanelli,Thomas Ernst,Nils Winkelman,Amy V. Jones,Amy V. Jones,Katerina Zoi,Andreas Reiter,Andrew S Duncombe,Laura Villani,Alberto Bosi,Giovanni Barosi,Nicholas C.P. Cross,Nicholas C.P. Cross,Alessandro M. Vannucchi +21 more
TL;DR: EZH2 mutations are independently associated with shorter survival in patients with PMF and in multivariate analysis, survival of PMF patients was predicted by IPSS high-risk category, a < 25% JAK2V617F allele burden, and EZh2 mutation status.
Journal ArticleDOI
Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial
Alan Kenneth Burnett,Robert Kerrin Hills,Donald Milligan,Anthony H. Goldstone,Archibald G. Prentice,Mary Frances McMullin,Andrew S Duncombe,Brenda Gibson,Keith Wheatley +8 more
TL;DR: Although transplantation reduced RR, it did not improve OS for the intermediate-risk group but was probably of benefit in high-risk patients, and several chemotherapy schedules achieved similar remission rates and OS.